Reducing Ischemia With CTO PCI: Good News, But Questions Remain.
Stéphane Rinfret, Pratik B Sandesara
https://pubmed.ncbi.nlm.nih.gov/34238552/Actively Recruiting
Led by Aarhus University Hospital Skejby · Updated on 2026-01-02
1560
Participants Needed
27
Research Sites
208 weeks
Total Duration
This research aims to evaluate the outcomes of treating chronic total occlusion CTO in coronary arteries, a condition linked to worse heart health compared to other coronary artery diseases. The study investigates whether using the latest drug-eluting stents in a procedure called Percutaneous Coronary Intervention PCI is better than optimal medical therapy OMT alone. It focuses on two groups asymptomatic patients with significant myocardial ischemia and symptomatic patients with moderate ischemia, to understand effects on major cardiovascular events and quality of life. All participants will begin with three months of optimal medical therapy. After this, they will be assigned to one of two groups based on symptoms and ischemia level Cohort A includes asymptomatic patients with at least 10% ischemia, randomized to PCI or continued OMT Cohort B includes symptomatic patients with at least 5% ischemia, also randomized to PCI or OMT, with the option for PCI after six months if symptoms persist. An additional Cohort C includes patients who do not meet criteria for randomization but will be followed in a registry. Participants will undergo regular follow-ups for up to five years in Cohort A and six months in Cohort B. Researchers will assess major adverse cardiovascular and cerebrovascular events MACCE and quality of life using the Seattle Angina Questionnaire. Before randomization, patients will be monitored for symptom class and ischemia levels using nuclear imaging. Safety and health status will be tracked through clinical visits, with the study aiming to provide clearer evidence on CTO treatment benefits and risks over time.
CONDITIONS
ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO
E
Evald Christiansen, MD PhD
E
Emil N Holck, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Aarhus University Hospital Skejby
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 months
Participants undergo a 3-month period of optimal medical therapy to stabilize their condition before randomization.
Duration - Up to 6 months or as per assigned treatment plan
Participants are randomized to receive either Percutaneous Coronary Intervention (PCI) or continue with optimal medical therapy (OMT) to manage chronic total occlusion.
1 baseline visit and follow-up visits depending on assigned treatment
Duration - Up to 10 years
Participants are followed to assess long-term outcomes including major adverse cardiovascular events and quality of life.
Periodic visits depending on cohort assignment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Stéphane Rinfret, Pratik B Sandesara
https://pubmed.ncbi.nlm.nih.gov/34238552/Aarhus University Hospital Skejby
Lead Sponsor